Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), C. Zamagni(Ospedale Santa Chiara), A. Caldara(Ospedale Santa Chiara), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Nadia Naldi(University of Parma), Renata Todeschini(University of Parma), Filippo Montemurro(Roche (Switzerland)), Federica Villa(Aziende Socio Sanitarie Territoriali di Lecco), Andrea Rocca(University of Trieste), Michele Tognetto(University of Aberdeen), Daniela Boggiani(University of Parma), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), Luca Boni(Ospedale Policlinico San Martino), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Aa Brandes(University of Modena and Reggio Emilia), Beatrice Bortesi(University of Parma), Benedetta Pellegrino(University of Parma), Jennifer Foglietta(Ospedale Santa Maria), Rossana Berardi(Marche Polytechnic University)
Cited by 2
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
|Proceedings of the National Academy of Sciences|2002|963
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
|Nature Medicine|2000|931